Clinical trials located in

Solna

Solna city is located in Sweden. Currently, 20 clinical trials are being conducted in this city.

Solna, nestled in Stockholm County, Sweden, boasts a rich tapestry of history and modernity. Home to the iconic Friends Arena and the majestic Haga Park, it seamlessly blends natural beauty with architectural marvels. Notably, it houses the Karolinska Institute, a world-renowned medical university. Solna’s demographic diversity and economic vitality, underscored by its status as one of Sweden’s lowest municipal tax rates, make it a vibrant community. The city also prides itself on the Solna Church, dating back to the 12th century, showcasing its deep historical roots.

  • CT-EU-00042123

    Testing a new drug for advanced prostate cancer

    This trial compares a new drug called AZD5305 with a placebo in men who have a specific kind of prostate cancer that has not responded to usual treatment methods. It’s a large trial, with around 1800 participants, and the main aim is to see whether the new treatment can help slow down the disease for longer than current treatments. Participants will be assigned to two different groups, and they will not know whether they’re receiving the real drug or the placebo. Their health will be monitored closely, with regular scans to check the progress of the cancer. The trial will also look at any side effects of the treatment and how it affects the patients’ ability to do their daily activities.

    • Enzalutamide/Xtandi
    • Darolutamide/Nubequa
    • Abiraterone Acetate/Zytiga
    • Saruparib
  • Study on new combination therapy for aggressive lymphoma

    This study is about a less common but severe form of cancer known as Diffuse Large B-Cell Lymphoma (DLBCL). It is testing if a new medication called epcoritamab, given with a mix of other commonly used cancer medicines, can help control the disease better. These other medicines include rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine, and prednisone, which are often collectively referred to as R-CHOP. The study includes about 900 adults from around the world who have recently been diagnosed with this type of lymphoma. They will be split into two groups. One group will get epcoritamab with R-CHOP and then continue with epcoritamab. The other group will get R-CHOP followed by rituximab. Doctors will carefully watch for changes in the disease and for any side effects. There will be many checks on health, including medical exams, blood tests, questionnaires, and monitoring of any side effects.

    • Prednisone
    • Vincristine
    • Doxorubicin
    • Epcoritamab
    • Cyclophosphamide
    • Rituximab
  • Research on medicine combination for B-cell Non-Hodgkin Lymphoma

    This study is about testing epcoritamab, a new drug for a type of blood cancer called B-cell Non-Hodgkin Lymphoma. The goal is to see if the drug is safe for people and can successfully fight the cancer. Doctors will combine this drug with other medicines that are typically used to treat this cancer. The combined treatment will vary for different groups of patients, depending on factors like their specific type of cancer or their overall health. Some patients will be given epcoritamab on its own, while others will receive it with other cancer medicines. The study has two parts. The first part is to find a safe dose of the drug. The second part is to determine how well this drug helps in treating the cancer. Side effects will be closely monitored during the study.

    • etoposide phosphate
    • oxaliplatin
    • Prednisone
    • Dexamethasone
    • Carboplatin
    • Epcoritamab
    • Ifosfamide
    • Cytarabine
    • Gemcitabine
    • Cyclophosphamide
    • Vincristine
    • Doxorubicin
    • Bendamustine
    • Lenalidomide
    • Rituximab
  • Comparison study of two melanoma treatments containing pembrolizumab

    This study compares two treatments for a type of skin cancer known as high-risk melanoma. Participants of this study have previously had this cancer surgically removed. The tested treatments are pembrolizumab with vibostolimab, and pembrolizumab alone. The aim is to find out which treatment is better at preventing the melanoma from returning or spreading to other parts of the body. Even after a successful surgery, some cancer cells may be left behind which could result in the cancer returning. The study is measuring the time it takes for the cancer to return and the time it takes for the cancer to spread far from where it started.

    • Vibostolimab
    • Pembrolizumab
  • Ponatinib treatment for children with various advanced cancers

    This trial focuses on a drug called ponatinib, that is being studied for the treatment of children (aged 1-18) with different harsh illnesses such as leukemias, lymphomas, and solid tumors. The researchers want to understand how safe the drug is, how well it works, and what happens to the drug in the body. Researchers will monitor any side effects that occur within the first 28 days of taking ponatinib. The researchers will also check if the drug is helping to reduce the illness by checking if there are fewer cancer cells in the body. The effects of the drug on the tumor will be monitored through scans like CT or MRI.

    • Ponatinib
  • Pemigatinib in the treatment of cholangiocarcinoma

    This study focuses on comparing the impact and safety of two treatments: Pemigatinib and a chemotherapeutic combination of Gemcitabine and Cisplatin. These treatments are being tested on people who have an advanced form of liver cancer, cholangiocarcinoma, which cannot be removed by surgery or has spread to other parts of the body, and is associated with a particular genetic change known as FGFR2 rearrangement. The aim is to examine the effectiveness of Pemigatinib in comparison to the chemotherapy combination of Gemcitabine and Cisplatin. Measurements of success will be based on how much the cancer shrinks, the duration of response to treatment, as well as any side effects encountered.

    • Pemigatinib
    • Gemcitabine
    • Cisplatin
  • Study on a new combination therapy for active ulcerative colitis

    This study aims to assess the effectiveness and safety of new combination therapy with JNJ-78934804 (Guselkumab/Golimumab) in comparison to guselkumab and golimumab administred alone for individuals with moderately to severely active ulcerative colitis. Participants who have shown inadequate response, loss of response, or intolerance to approved advanced therapies will be included. The trial includes various treatment groups: placebo, Guselkumab, Golimumab, and different doses of JNJ-78934804. All participants meeting inadequate response criteria will be escalated to an active treatment. The study will last for 48 weeks and the progress will be tracked over this period. The primary focus is to evaluate the efficacy and safety of the different doses of new therapy in managing ulcerative colitis over the course of the study.

    • JNJ-78934804/guselkumab + golimumab
    • Golimumab
    • Guselkumab
  • Studying rimegepant’s effectiveness on Migraine

    This study is testing a new treatment, rimegepant, for adults with migraines who cannot take traditional migraine medications, such as triptans, possibly due to reasons like having a heart condition. The research aims to evaluate the effectiveness and tolerability of rimegepant over a 12-week period. Participants will be asked to rate their headache pain on a scale ranging from 0 (no pain) to 3 (severe pain) as one of the methods to assess the treatment’s impact.

    • Rimegepant
  • Deucravacitinib: A possible solution for active Sjögren’s Syndrome

    The study aims to evaluate the effectiveness and safety of the medication Deucravacitinib, also known as BMS-986165, in adults diagnosed with Active Sjögren’s Syndrome, a condition characterized by symptoms like dry eyes and mouth. The study is designed to understand how well Deucravacitinib can alleviate these symptoms compared to a placebo. This is done over a series of regular checks over time to monitor the improvement in symptoms and the overall safety of the medication for participants.

    Deucravacitinib will be given in two different doses to different groups of participants to determine which dose is more effective. Those on the placebo will later receive one of the doses of Deucravacitinib. The study will assess changes in various symptoms and measures of disease activity at several points during the study, providing insights into both the short-term and longer-term effects of the treatment.

    Throughout the study, participants will have their symptoms monitored and will undergo various assessments to see if there is any improvement in their condition and to check for any possible side effects from the medication. This includes checking the severity of their symptoms, overall health, and any changes in their body’s response to the treatment.

    • Deucravacitinib
  • Comparison of different treatments for follicular lymphoma

    This study involves comparing two treatments for a condition known as follicular or marginal zone lymphoma, both of which are types of cancer affecting lymph cells. The first treatment combines zanubrutinib with an antibody called Anti-CD20, while the second treatment involves lenalidomide and rituximab. These treatments are intended for patients who have not responded or have stopped responding to conventional treatment. One of the primary objectives of the study is to determine which treatment is more effective in preventing the cancer from progressing, referred to as progression-free survival. Additionally, the study aims to assess the impact of these treatments on the patients’ quality of life, evaluating various aspects through questionnaires related to physical and emotional well-being, symptoms, and the ability to perform normal activities.

    • Zanubrutinib
    • Obinutuzumab
    • Lenalidomide
    • Rituximab
  • Study on dazostinag & pembrolizumab for advanced solid tumors

    The purpose of this study is to test a new drug called dazostinag. A study is being conducted to see whether this drug is helpful in adults with advanced forms of solid cancer. Some people are given dazostinag alone, while others are given it with another medicine called pembrolizumab. Scientists’ focus here is on finding out whether these drugs cause any side effects, and finding out what the maximum dose is that people can take without serious side effects. The study consists of two parts, including a dose escalation phase and a dose escalation phase. In the first part, the dose of dazostinag will be gradually increased, given alone or in combination with pembrolizumab. In the second part, Dazostinag will be tested with pembrolizumab and other anticancer drugs. This section will focus on patients with specific cancers that are difficult to remove or have spread to other parts of the body.

    • Dazostinag
    • Platinum
    • Pembrolizumab
    • 5-Fluorouracil
  • Combination therapy trial for moderately to severely active Crohn’s disease

    The study examines a combination therapy using guselkumab and golimumab in individuals with active Crohn’s Disease. It aims to compare the effectiveness of this dual approach to individual treatments, focusing on reducing disease symptoms and improving patients’ quality of life. The study’s goal is to offer new hope and better management strategies for those battling this challenging condition.

    • JNJ-78934804 (guselkumab, golimumab)
    • Golimumab
    • Guselkumab
  • Study on carfilzomib effect on children’s leukemia

    This clinical trial focuses on children who face the difficult situation of acute lymphoblastic leukemia (ALL), a type of blood cancer. When cancer returns or does not respond to standard treatments, doctors call it relapsed or refractory, and it can be difficult to treat. The study is evaluating a drug called carfilzomib, which is being tested alongside common chemotherapy drugs. The drugs used in the clinical trial include carfilzomib, dexamethasone, mitoxantrone, PEG-asparaginase, vincristine, Intrathecal Methotrexate, Intrathecal Triple Therapy (Intrathecal Cytarabine, Hydrocortisone, and Methotrexate), 6-mercaptopurine, cyclophosphamide, cytarabine, and daunorubicin. The process has two main goals. First, he wants to find an appropriate dose of carfilzomib that is safe for children. This is significant because finding the right dose means balancing effectiveness with minimizing side effects. Once a safe dose is determined, the second part of the study begins. This part is about seeing how well carfilzomib works when it is part of a treatment regimen. Doctors and researchers will carefully monitor the children’s response to treatment. They will check whether the cancer responds to the new approach and how the children’s bodies cope with it. They will also track any side effects to ensure your treatment is safe.

    • Methotrexate
    • Hydrocortisone
    • Cytarabine
    • Daunorubicin
    • Carfilzomib
    • Mitoxantrone
    • PEG-asparaginase
    • Intrathecal (IT) Methotrexate
    • 6-Mercaptopurine
    • Vincristine
    • Dexamethasone
    • Cyclophosphamide
  • Advanced cancer therapy study: Zenocutuzumab’s role in tumor control

    The research is being conducted on the drug zenocutuzumab (MCLA-128) to assess its potential effectiveness for patients with certain types of cancer characterized by an NRG1 fusion. The study involves administering varying doses of the drug to evaluate its safety and assess the body’s response. Additionally, the drug is being tested on patients with specific cancer types, such as NSCLC and pancreatic cancer, which exhibit the NRG1 fusion. The study will closely monitor the impact of the drug on the body, specifically examining its ability to halt or reduce cancer growth. Progress will be tracked through regular check-ups for up to two years after the final drug dose.

    • zenocutuzumab
  • Testing astegolimab’s effectiveness in chronic obstructive pulmonary disease patients

    A clinical research study is being conducted to examine the efficacy and safety of a novel treatment known as astegolimab in the management of Chronic Obstructive Pulmonary Disease (COPD). The study is particularly focused on individuals with a history of COPD who are either current or former smokers and have experienced frequent exacerbations. Within the scope of this study, astegolimab’s therapeutic potential is being compared to that of a placebo. Participants enrolled in the trial will be administered the study medication at intervals of either every 2 or 4 weeks. Key parameters under evaluation include the frequency of COPD exacerbations, variations in the quality of life of the participants, and changes in lung function over the course of the study. The study aims to contribute valuable data to medical research, particularly in understanding the treatment dynamics of astegolimab in COPD management.

    • Astegolimab
  • Effects of new drug on metastatic prostate cancer

    This trial studies the effect of AZD5305 plus physician-chosen hormonal agents versus placebo in men with metastatic castration-sensitive prostate cancer (mCSPC). Around 1800 adult men with mCSPC are being enrolled and divided into two groups: those receiving AZD5305 and those receiving a placebo, both alongside standard hormonal treatments. Safety and treatment effects will be monitored. The goal is to find out if this new drug combination helps patients live longer without their cancer getting worse.

    • Darolutamide
    • Enzalutamide
    • Saruparib
    • Abiraterone Acetate
  • Testing a new trio of drugs for advanced and metastatic breast cancer

    This study, known as CAPItello-292, is testing a new combination of drugs to see if it can help treat advanced or spreading breast cancer. The drugs include one called capivasertib along with two others known as CDK4/6 inhibitors and another drug called fulvestrant. The study wants to see how well these work together and how safe they are. Firstly, they need to decide on the best dose of these drugs to use together. Then, the main part of the study will compare these drugs with the usual treatment – either of the CDK4/6 inhibitors with fulvestrant — to see which is better. Scientists will check the blood of the patients to see how much of the drugs are present. They also want to see how many people have side effects and how severe these are. Patients’ health will also be monitored, including heart tests, blood tests and checking vital signs. The ultimate goal is to see if this new treatment can slow down the growth of the cancer, or even shrink it. In simpler words, this is a study for people with a type of advanced breast cancer. It’s testing three drugs together — capivasertib, a CDK4/6 inhibitor, and fulvestrant. This study is made up of two parts. The first part is to decide on the right amount of these drugs to give at the same time. Then, they’ll test this against the usual treatment to see if it’s better. They’ll use blood tests to check how much of the drugs are in the body and will carefully watch for any side effects. They’ll also keep a close eye on people’s health overall. The main aim is to see if this new combination can stop the cancer from getting worse. The CAPItello-292 trial is aimed at patients with serious breast cancer that has started to spread. In this research, a new blend of three medicines, capivasertib, a CDK4/6 inhibitor, and fulvestrant, is being evaluated. First, researchers want to figure out the optimal dosing of these drugs when taken together. Then they’ll compare this combination to the standard treatment to see if it provides any additional benefits. They’ll take blood tests to track the amount of medication and continuously monitor for any potential side effects. The end goal is to see if this new drug mixture can slow or even decrease the growth of the cancer.

    • Capivasertib
    • Abemaciclib
    • Palbociclib
    • Ribociclib
    • Fulvestrant
  • Exploring physical activity and joint health in Haemophilia A patients using efanesoctocog alfa

    This study is called FREEDOM, and it’s investigating how physical activity and joint health are impacted in people aged 12 and above who have severe Haemophilia A, a bleeding condition. These people are treated with a drug called efanesoctocog alfa once a week over a two-year period. Participants will wear a device that tracks their activity, and they will also keep an electronic diary recording any bleeding, pain, injuries they have and how much of the drug they’re taking. The study is mainly comparing how physical activity changes over the two-year period, but it’ll also examine changes in joint health, occurrences of bleeds, injuries, and pain, along with the general safety of the drug.

    • Efanesoctocog alfa
  • Study of new drugs in acute lymphoblastic leukemia

    This clinical trial focuses on improving treatment strategies for acute lymphoblastic leukemia (ALL) in a diverse age group, from infants to young adults up to 45 years old. The study combines standard treatments with new drugs, for example, Inotuzumab Ozogamicin and Blinatumomab. The trial aims to tailor treatment to individual patient needs and reduce toxicity while maintaining treatment quality. By carefully monitoring event- and disease-free survival rates, as well as minimal residual disease responses, the trial aims to improve the standard of care for ALL and improve both survival outcomes and patient quality of life.

    • Inotuzumab Ozogamicin
    • 6-tioguanine
    • Blinatumomab
    • Imatinib
    • Dexamethasone
    • Vincristine
    • Doxorubicin
  • Exploring sacituzumab govitecan for HER2-negative breast cancer care

    This study is evaluating a new treatment for patients with a certain type of breast cancer (HER2-negative) who have not had a complete response to initial chemotherapy. Participants are randomly assigned to receive the investigational drug sacituzumab govitecan or a treatment of their physician’s choice, which may be another type of chemotherapy with capecitabinalub, carboplatin or cisplatin. The study is designed to compare the effectiveness of these approaches in preventing cancer recurrence. Patients may also receive hormone therapy if needed. Patients’ safety and response to treatment are being closely monitored throughout the study.

    • Sacituzumab govitecan
    • Carboplatin
    • Cisplatin
    • Capecitabine

See more clinical trials in other cities in Sweden:

.